Drug intelligence / Profile preview

latanoprost + dorzolamide + timolol

Development stage
Unknown
Lead developer
Pfizer
Modality
Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Ophthalmic
01

Overview

The combination of latanoprost, dorzolamide, and timolol is an ophthalmic solution used to treat increased intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This triple combination leverages different mechanisms of action to effectively lower eye pressure. ## Composition and Mechanism This medication combines three active ingredients: - **Latanoprost** (0.05 mg/mL): A prostaglandin analog that increases the outflow of aqueous fluid from the eye through the uveoscleral pathway[7] - **Dorzolamide** (20 mg/mL): A carbonic anhydrase inhibitor that decreases the production of aqueous fluid in the eye[3][5] - **Timolol** (5 mg/mL): A non-selective beta blocker that blocks both beta-1 and beta-2 receptors in the eye, reducing aqueous fluid production[3][6] ## Clinical Effectiveness Studies have shown that this triple combination can be effective for patients whose eye pressure is not adequately controlled with monotherapy. The combination can provide significant IOP reduction, with one study showing a mean IOP decrease of 6.3 \u00b1 3.6 mm Hg (28.1%) when dorzolamide-timolol was added to existing latanoprost therapy[2]. ## Administration The medication is typically administered as eye drops, with one drop placed in the affected eye(s) twice daily[1][5]. Proper administration technique is important to maximize effectiveness and minimize systemic absorption. ## Side Effects Common side effects may include: - Eye irritation (12.0% of patients) - Taste perversion (4.3% of patients) - Blurry vision - Itchy eyes[2][6] Most adverse events are mild and non-serious. No serious adverse events related to this medication were reported in the studies reviewed[2]. ## Availability This combination is available as a prescription medication. It may be found as a branded product (TIM-DOR-LAT) or as a compounded medication[1]. Some versions are available in preservative-free formulations for patients who may be sensitive to preservatives[1][6].

Brand names
TIM-DOR-LAT
Other names
dorzolamide/latanoprost/timolol ophthalmic
02

Targets

ADRB1 (β1)ADRB2 (β2)CA2 (Carbonic Anhydrase 2)PTGFR (Prostaglandin F2 alpha receptor)CA1 (Carbonic anhydrase 1)

Beyond the preview

Go deeper on latanoprost + dorzolamide + timolol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on latanoprost + dorzolamide + timolol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call